Victory Capital Management Inc. Acquires Shares of 346,490 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Victory Capital Management Inc. purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 346,490 shares of the company's stock, valued at approximately $12,328,000. Victory Capital Management Inc. owned 0.54% of IDEAYA Biosciences at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Alps Advisors Inc. increased its position in shares of IDEAYA Biosciences by 0.9% in the 3rd quarter. Alps Advisors Inc. now owns 42,479 shares of the company's stock valued at $1,146,000 after purchasing an additional 368 shares during the last quarter. Amalgamated Bank raised its stake in IDEAYA Biosciences by 6.4% in the third quarter. Amalgamated Bank now owns 7,205 shares of the company's stock valued at $194,000 after buying an additional 433 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in IDEAYA Biosciences by 2.5% during the 3rd quarter. Los Angeles Capital Management LLC now owns 18,802 shares of the company's stock worth $507,000 after buying an additional 456 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of IDEAYA Biosciences by 2.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,797 shares of the company's stock valued at $669,000 after acquiring an additional 486 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of IDEAYA Biosciences by 4.0% during the 3rd quarter. Arizona State Retirement System now owns 13,865 shares of the company's stock worth $374,000 after acquiring an additional 536 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA traded up $0.53 during mid-day trading on Friday, reaching $41.17. The stock had a trading volume of 446,904 shares, compared to its average volume of 642,890. The business has a 50 day simple moving average of $42.38 and a 200 day simple moving average of $38.60. IDEAYA Biosciences, Inc. has a twelve month low of $20.68 and a twelve month high of $47.74. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -20.48 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. IDEAYA Biosciences's revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.49) earnings per share. As a group, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -2.33 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on IDYA shares. Citigroup increased their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, March 21st. Royal Bank of Canada lifted their price target on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 21st. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Leerink Partnrs reiterated an "outperform" rating on shares of IDEAYA Biosciences in a research note on Friday, February 23rd. Finally, Capital One Financial restated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $47.50.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.